{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:42:59Z","timestamp":1787506979226,"version":"build-2736575974"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Systemic sclerosis (SSc) is a rare and heterogeneous disease with no relevant environmental trigger or significant responsible gene. It has been and will continue to be difficult to identify large enough patients to conduct classic population-based epidemiologic exposure\/non-exposure studies with adequate power to ascertain environmental and genetic risk factors for these entities. The complexity of pathogenesis and heterogeneity are likely to require personalized\/precision medicine for SSc. Since several potential drugs are currently available for specific patients if not whole SSc, classification of SSc seems to form the foundation for a better therapeutic strategy. To date, SSc has been classified based on the extent\/severity of the affected area as well as some disease markers, including the autoantibody profile. However, such an analysis should also lead to improvements in the design of appropriately stratified clinical trials to determine the effects and prediction of targeted therapies. An approach based on drug response preclinically conducted using patients\u2019 own fibroblasts\n                    <jats:italic>in vitro<\/jats:italic>\n                    , can provide a precise disease marker\/therapeutic selection for clinical practice. Because scleroderma dermal fibroblasts have a persistent hyper-productive phenotype occurring not only in person, but also in cell culture conditions. Thus, an accumulating approach based on disease markers ensures progression and de-escalation to re-establish a better life with a personally optimized drug environment after the onset of SSc.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1298665","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T23:43:01Z","timestamp":1705534981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Perspective to precision medicine in scleroderma"],"prefix":"10.3389","volume":"14","author":[{"given":"Kazuhiro","family":"Komura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yanaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(75)90017-7","article-title":"Pathogenesis of systemic sclerosis: A vascular hypothesis","volume":"4","author":"Campbell","year":"1975","journal-title":"Semin Arthritis Rheu"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390712","article-title":"Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). an immunogenetic, serologic, and clinical analysis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheumatism"},{"key":"B3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/08916939908994064","article-title":"Autoimmunity and vascular involvement in systemic sclerosis (SSc)","volume":"31","author":"Kahalefp","year":"2009","journal-title":"Autoimmunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci107827","article-title":"Increased collagen synthesis by scleroderma skin fibroblasts in vitro a possible defect in the regulation or activation of the scleroderma fibroblast","volume":"54","author":"LeRoy","year":"1974","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.135.6.1351","article-title":"Connective tissue synthesis by scleroderma skin fibroblasts in cell culture","volume":"135","author":"Leroy","year":"1972","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0006-291x(05)81456-1","article-title":"Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: Insensitivity to TGF\u03b21 stimulation","volume":"187","author":"Kikuchi","year":"1992","journal-title":"Biochem Bioph Res Co"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.34376","article-title":"DNA demethylation of CD40L in CD4+ t cells from women with systemic sclerosis: A possible explanation for female susceptibility","volume":"64","author":"Lian","year":"2012","journal-title":"Arthritis Rheumatism"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9647-y","article-title":"MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma","volume":"32","author":"Zhu","year":"2012","journal-title":"J Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200822","article-title":"The downregulation of microRNA let-7a contributes to the excessive expression of type i collagen in systemic and localized scleroderma","volume":"190","author":"Makino","year":"2013","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073387","article-title":"Blockade of CD40\/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse","volume":"67","author":"Komura","year":"2008","journal-title":"Ann Rheumatic Dis"},{"key":"B11","article-title":"Elevated circulating CD40L concentrations in patients with systemic sclerosis","volume":"31","author":"Komura","year":"2004","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2018.01.003","article-title":"Epigenetics and pathogenesis of systemic sclerosis; the ins and outs","volume":"79","author":"Aslani","year":"2018","journal-title":"Hum Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12595","article-title":"Epigenetics: The future direction in systemic sclerosis","volume":"86","author":"Walczyk","year":"2017","journal-title":"Scand J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8534-y","article-title":"Critical link between epigenetics and transcription factors in the induction of autoimmunity: a comprehensive review","volume":"50","author":"Wu","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.07.042","article-title":"Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions","volume":"28","author":"Miao","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu155","article-title":"Epigenetics, the holy grail in the pathogenesis of systemic sclerosis","volume":"54","author":"Altorok","year":"2015","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"gene201444","DOI":"10.1038\/gene.2014.44","article-title":"Emerging role of epigenetics in systemic sclerosis pathogenesis","volume":"15","author":"Ciechomska","year":"2014","journal-title":"Genes Immun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.01.012","article-title":"Systemic sclerosis: genetics and epigenetics","volume":"41","author":"Luo","year":"2013","journal-title":"J Autoimmun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5439.481","article-title":"Epigenetics: Regulation through repression","volume":"286","author":"Wolffe","year":"1999","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.39830","article-title":"Editorial: Epigenetics in systemic sclerosis","volume":"68","author":"Lafyatis","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci Signal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.09.023","article-title":"miR-150 down-regulation contributes to the constitutive type i collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin \u03b23","volume":"182","author":"Honda","year":"2013","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.30284","article-title":"The c-abl tyrosine kinase controls protein kinase c\u03b4\u2013induced fli-1 phosphorylation in human dermal fibroblasts","volume":"63","author":"Bujor","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000111507","article-title":"The effect of imatinib (GlivecR) on scleroderma and normal dermal fibroblasts: A preclinical study","volume":"216","author":"Soria","year":"2008","journal-title":"Dermatology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.23698","article-title":"Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate","volume":"58","author":"Pannu","year":"2008","journal-title":"Arthritis Rheumatism"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615990113","article-title":"Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer","volume":"113","author":"Xu","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","article-title":"PPAR\u03b3 downregulation by TGFs in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci111480","article-title":"Selective inhibition of human diploid fibroblast collagen synthesis by interferons","volume":"74","author":"Jimenez","year":"1984","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300407","article-title":"Procollagen gene expression by scleroderma fibroblasts in culture. inhibition of collagen production and reduction of pro\u03b1(i) and pro\u03b11(III) collagen messenger RNA steady-state levels by retinoids","volume":"30","author":"Ohta","year":"1987","journal-title":"Arthritis Rheumatism"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J Investig Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: A randomized, double-blind, placebo-controlled trial of c-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti\u2013transforming growth factor \u03b21 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebocontrolled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40246-017-0119-1","article-title":"Precision medicine at the crossroads","volume":"11","author":"Olson","year":"2017","journal-title":"Hum Genom"},{"key":"B39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/msb.2009.32","article-title":"Personal phenotypes to go with personal genomes","volume":"5","author":"Snyder","year":"2009","journal-title":"Mol Syst Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tips.2016.10.012","article-title":"Towards precision medicine in the clinic: From biomarker discovery to novel therapeutics","volume":"38","author":"Collins","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.09.79","article-title":"Biomarkers in systemic sclerosis","volume":"4","author":"Castro","year":"2010","journal-title":"Biomark Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220402","article-title":"Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis","volume":"80","author":"Clark","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez244","article-title":"Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis","volume":"58","author":"Kubo","year":"2019","journal-title":"Rheumatology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(76)90410-1","article-title":"Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), raynaud\u2019s syndrome and dermatomyositis","volume":"61","author":"Maricq","year":"1976","journal-title":"Am J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.12.007","article-title":"A functional genomic meta-analysis of clinical trials in systemic sclerosis: Toward precision medicine and combination therapy","volume":"137","author":"Taroni","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114017","article-title":"Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts","volume":"10","author":"Johnson","year":"2015","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01602","article-title":"Systemic sclerosis perturbs the architecture of the immunome","volume":"11","author":"Paleja","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmms1817082","article-title":"The future of gene editing \u2014 toward scientific and social consensus","volume":"380","author":"Rosenbaum","year":"2019","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0030","DOI":"10.5041\/rmmj.10257","article-title":"Targeted therapy in systemic sclerosis","volume":"7","author":"Baron","year":"2016","journal-title":"Rambam Maimonides Med J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065x.2008.00646.x","article-title":"B-lymphocyte contributions to human autoimmune disease","volume":"223","author":"Yanaba","year":"2008","journal-title":"Immunol Rev"},{"key":"B56","first-page":"59","article-title":"Polyclonal b lymphocyte activation in progressive systemic sclerosis","volume":"29","author":"Famularo","year":"1989","journal-title":"J Clin Lab Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/art.20274","article-title":"Altered blood b lymphocyte homeostasis in systemic sclerosis: Expanded naive b cells and diminished but activated memory b cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of fc\u03b3 receptors regulates b lymphocyte depletion during CD20 immunotherapy","volume":"203","author":"Hamaguchi","year":"2006","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes b lymphocytes through fc receptor\u2013dependent mechanisms during AntiCD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type i and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.09.003","article-title":"Is there a role for b-cell depletion as therapy for scleroderma? a case report and review of the literature","volume":"40","author":"Daoussis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12461","article-title":"Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus","volume":"41","author":"Sumida","year":"2014","journal-title":"J Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of b cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120778","article-title":"Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the european scleroderma trial and research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(22)00131-x","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e200124","DOI":"10.1212\/nxi.0000000000200124","article-title":"International delphi consensus on the management of AQP4-IgG+ NMOSD","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501376","article-title":"Autoreactive CD19+CD20\u2013 plasma cells contribute to disease severity of experimental autoimmune encephalomyelitis","volume":"196","author":"Chen","year":"2016","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR t cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.06.001","article-title":"Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib","volume":"42","author":"Bournia","year":"2013","journal-title":"Semin Arthritis Rheumatism"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/jci19603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGFbeta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, openlabel pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"B79","doi-asserted-by":"publisher","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/1346-8138.13026","article-title":"Strategy for treatment of fibrosis in systemic sclerosis: Present and future","volume":"43","author":"Yanaba","year":"2016","journal-title":"J Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00904-4","article-title":"Paradoxical reactions to anti-TNF\u03b1 and anti-IL-17 treatment in psoriasis patients: Are skin and\/or gut microbiota involved","volume":"13","author":"Zakostelska","year":"2023","journal-title":"Dermatol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.41627","article-title":"Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis\u2013related interstitial lung disease","volume":"73","author":"Assassi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac023","article-title":"Predictors of rituximab effect on modified rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial","volume":"61","author":"Ebata","year":"2022","journal-title":"Rheumatology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1037-4","article-title":"A dominant negative PPAR\u03b3 mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells","volume":"46","author":"Park","year":"2003","journal-title":"Diabetologia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-\u03b3 agonist triterpenoid ameliorates experimental fibrosis: PPAR-\u03b3-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B90","article-title":"Precision medicine for patients with systemic sclerosis","volume":"1","author":"Komura","year":"2016","journal-title":"J Scleroderma Related Disord"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00864-7","article-title":"Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis","volume":"18","author":"Fang","year":"2022","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1298665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T23:43:05Z","timestamp":1705534985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1298665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2023.1298665"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1298665","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"article-number":"1298665"}}